ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer Compounds
Company to Develop TAP Compound to Novel Target Using Centocor Antibody
08-Jan-2008 -
ImmunoGen, Inc. announced that it has licensed the exclusive right to develop and commercialize a TAP compound to a novel target using an antibody created by Centocor. This license supersedes the previous agreement between the companies.
Under the terms of the agreement, ImmunoGen gains the ...
angiogenesis
antibodies
Centocor
+4